IP Library › Granted Patent US 10,420,676
Granted Patent B2
US 10,420,676 · App. 15/103,213 · Granted Sep 24, 2019

Ophthalmic treatment device, method for controlling ophthalmic treatment device, and fundus lesion treatment method

Inventor: Jong Min Kim (Seoul, KR)
Assignee: LUTRONIC VISION INC.
A61F9/008A61F2009/00863A61F2009/00897
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,420,676
App. No.
15/103,213
Granted
Sep 24, 2019
Kind
B2
Abstract

The present invention relates to an ophthalmic treatment device, a control method therefor and a fundus lesion treatment method, the ophthalmic treatment device comprising: a treatment beam generation unit for generating a treatment beam; a beam delivery unit for forming a path through which the treatment beam generated from the treatment beam generating unit is irradiated into a patient's fundus; and a control unit for controlling the beam delivery unit to irradiate the treatment beam into a location adjacent to the lesion area of the fundus.

Claims (26)

1. An ophthalmic treatment device, comprising:

a treatment beam generation unit that generates a treatment beam;

a beam delivery unit that forms a path that radiates the treatment beam generated in the treatment beam generation unit to a patient's fundus; and

a controller that controls the beam delivery unit to radiate the treatment beam to one or more locations adjacent to a lesion area of the fundus, the one or more locations being outside the lesion area and separated by a predetermined gap or more from a boundary of the lesion area,

wherein the controller controls to radiate the treatment beam to the one or more locations that are separated by at least one RPE cell size from the boundary of the lesion area so as to prevent the lesion area from expanding, and

wherein the lesion area of the fundus is any one of an area in which geography angiography has occurred, an area in which drugen is formed, an area in which blood leakage has occurred, and an area in which macular edema is formed.

2. The ophthalmic treatment device of claim 1 , wherein the treatment beam transfers energy to a depth in which an RPE cell layer is located at the patient's fundus.

3. The ophthalmic treatment device of claim 1 , wherein the controller controls to radiate the treatment beam along a pattern that partitions between the lesion area and a center of the fundus.

4. The ophthalmic treatment device of claim 1 , wherein the one or more locations form a pattern separated by the predetermined gap or more from the boundary of the lesion area.

5. The ophthalmic treatment device of claim 1 , wherein the controller controls to radiate the treatment beam in a pattern separated by 10 μm or more from the boundary of the lesion area.

6. The ophthalmic treatment device of claim 1 , wherein the one or more locations are separated by 10-200 μm from the boundary of the lesion area.

7. The ophthalmic treatment device of claim 1 , wherein a pattern of the treatment beam encloses the lesion area.

8. The ophthalmic treatment device of claim 7 , wherein the pattern of the treatment beam forms a closed curve that encloses the lesion area.

9. The ophthalmic treatment device of claim 4 , wherein the pattern comprises a first pattern and a second pattern, and the second pattern is separately located further than the first pattern from the boundary of the lesion area.

10. The ophthalmic treatment device of claim 9 , wherein a radiation gap of a treatment beam constituting the first pattern is smaller than that of a treatment beam constituting the second pattern.

11. The ophthalmic treatment device of claim 1 , wherein the treatment beam includes a plurality of beams, and the controller controls to sequentially radiate the plurality of beams at the same location and controls a parameter of the treatment beam.

12. The ophthalmic treatment device of claim 11 , wherein the parameter of the treatment beam is any one of an output, a beam size, and a pulse pattern of the treatment beam.

13. A method of treating a fundus lesion, the method comprising:

determining a lesion area using a patient's fundus image; and

radiating a treatment beam to a plurality of locations adjacent to a boundary of the lesion area,

wherein the radiating of the treatment beam comprises radiating the treatment beam at the plurality of locations separated by a predetermined gap or more from the boundary of the lesion area, and

wherein the plurality of locations where the treatment beam is radiated are separated by at least one RPE cell size from the boundary of the lesion area so as to prevent the lesion area from expanding, and

wherein the lesion area of the fundus is any one of an area in which geography angiography has occurred, an area in which drugen is formed, an area in which blood leakage has occurred, and an area in which macular edema is formed.

14. The method of claim 13 , wherein the radiating of the treatment beam comprises radiating the treatment beam in a form that partitions between the lesion area and a center of the fundus.

15. The method of claim 13 , wherein the radiating of the treatment beam comprises radiating the treatment beam in a closed curve that encloses the lesion area.

16. The method of claim 13 , wherein the location is outside the lesion area.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2025
From: LUTRONIC VISION INC.
To: R:GEN VISION, INC.
Reel/Frame 072164/0141 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 2, 2017
From: LUTRONIC CORPORATION
To: LUTRONIC VISION INC
Reel/Frame 044023/0781 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2016
From: KIM, JONG MIN
To: LUTRONIC CORPORATION
Reel/Frame 038963/0589 →
Continuity (2)
Provisional Application 61913902 · Dec 9, 2013
Related Publication 20160331585A1 · Nov 17, 2016
Cited By (1)
US 12,396,887